Eli Lilly's Billion-Dollar Bet on Verve: Early Heart Drug Data
Decision brief
Answer first · skim in under a minute
Eli Lilly's early data on the heart drug Verve underscores its significant investment potential. This article explores the implications for pharma teams and investors.
Eli Lilly's billion-dollar bet on Verve now has early heart disease data: May 25, 2026, Heart-2 Phase 1b results for VERVE-102 showed up to 88% PCSK9 and 62% LDL-C mean reductions after one infusion, following Lilly's July 25, 2025 Verve close.
Contents10 sections
Key Takeaways
- Lilly completed the Verve Therapeutics acquisition on July 25, 2025.
- Heart-2 interim data (35 participants) showed dose-dependent mean PCSK9 cuts of 51%–88% and LDL-C cuts up to 62% at 1.0 mg/kg.
- Reductions were reported as durable for up to 18 months in follow-up.
- No treatment-related serious adverse events or dose-limiting toxicities were reported in the interim cutoff.
- Lilly said it plans to begin Phase 2 enrollment for VERVE-102 by the end of 2026; FDA Fast Track designation was disclosed.
What happened with Lilly's Verve acquisition?
Lilly's July 25, 2025 investor release said it completed acquiring Verve Therapeutics, a clinical-stage developer of genetic medicines for cardiovascular disease.
Verve's programs target lipoprotein drivers of atherosclerosis, including PCSK9 (VERVE-102), ANGPTL3 (VERVE-201), and lipoprotein(a) via VERVE-301.
SEC filings around the tender offer and merger, including Verve's July 2025 Form 8-K, document the closing path under Delaware Section 251(h).
What did the Heart-2 VERVE-102 data show?
On May 25, 2026, Lilly reported Phase 1b Heart-2 interim results in a PR Newswire / Lilly release.
Among 35 participants with heterozygous familial hypercholesterolemia or premature coronary artery disease, mean PCSK9 reductions ranged from 51% at 0.3 mg/kg to 88% at 1.0 mg/kg.
Corresponding mean LDL-C reductions were 9%, 44%, 45%, 33%, 51%, and 62% across the 0.3 to 1.0 mg/kg cohorts.
Durability was observed for up to 18 months. Median follow-up was about nine months as of a February 27, 2026 data cut, with 15 participants followed for at least one year.
How does VERVE-102 work against heart disease risk?
VERVE-102 packages messenger RNA encoding an adenine base editor with a PCSK9-targeting guide RNA inside a GalNAc lipid nanoparticle.
The design aims to mimic naturally occurring PCSK9 loss-of-function variants linked to lower lifetime coronary risk, delivering a one-time rather than chronic LDL-lowering course.
Heart disease remains a leading global killer. For disease background and related coverage, see NovaPharma's heart disease entity page.
What safety signals were reported so far?
Lilly said VERVE-102 was well tolerated across dose levels, with no treatment-related serious adverse events and no dose-limiting toxicities in the interim analysis.
Related adverse events included low-grade infusion-related reactions and fatigue. All participants received the full planned dose; none withdrew for the reported cutoff.
These are early Phase 1b findings. Larger controlled studies are required before any comparative claim versus chronic PCSK9 monoclonal antibodies or siRNA therapies.
What is next for Lilly's cardiovascular gene-editing franchise?
Lilly said it plans to start Phase 2 enrollment for VERVE-102 by the end of 2026.
FDA Fast Track designation for reducing LDL-C in people with hyperlipidemia and high lifetime cardiovascular risk was disclosed in the same May 2026 readout.
Parallel work continues on VERVE-201 (ANGPTL3) in the Pulse-1 Phase 1b trial. Competitive watchers should also track Lilly Alzheimer's approval news and retatrutide Phase 3 competitive readouts for capital-allocation context.
How do Heart-2 results compare with chronic PCSK9 drugs?
Chronic monoclonal antibodies and siRNA products already lower LDL cholesterol with repeated dosing. VERVE-102 seeks a one-time edit instead.
Cross-trial comparisons are unreliable at Phase 1b. The interim Heart-2 cohort is small (35 participants), open-label, and dose-ranging. Absolute LDL-C reduction of 78 mg/dL at the highest dose is notable but must be confirmed in controlled Phase 2 work.
For protocol detail, see NCT06164730 on ClinicalTrials.gov. Peer-reviewed context was also published alongside the EAS presentation in the New England Journal of Medicine per Lilly's May 25, 2026 disclosure.
What commercial questions remain for payers?
Even if Phase 2 succeeds, payers will ask about durability beyond 18 months, re-dosing rules if LDL rebounds, and long-term safety follow-up that Lilly said may extend to 15 years for Heart-2 participants.
One-time gene editing also raises unique coding and reimbursement questions versus monthly or twice-yearly chronic therapies. Those issues are unresolved at this Stage of development and should not be modeled as settled.
Frequently Asked Questions
What early VERVE-102 data did Lilly report?
In a May 25, 2026 interim Heart-2 Phase 1b analysis of 35 participants, VERVE-102 showed dose-dependent mean PCSK9 reductions of 51% to 88% and LDL-C reductions up to 62% at 1.0 mg/kg, with durability up to 18 months.
When did Lilly complete the Verve acquisition?
Eli Lilly announced completion of its acquisition of Verve Therapeutics on July 25, 2025, making Verve a wholly owned subsidiary focused on genetic medicines for cardiovascular disease.
What is VERVE-102 designed to do?
VERVE-102 is an investigational in vivo base editing medicine designed to turn off the PCSK9 gene in the liver after a single intravenous infusion to lower LDL cholesterol.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
